C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: Relative findings and response to therapy

Clinical Nuclear Medicine

Volumn 36, Issue 3, 2011, Pages 192-198

  Yu, Evan Y ^a   Muzi, Mark ^a   Hackenbracht, Joy A ^a   Rezvani, Brian B ^a   Link, Jeanne M ^a   Montgomery, Robert Bruce ^a   Higano, Celestia S ^a   Eary, Janet F ^a   Mankoff, David A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

bone metastases; C11 acetate (acetate); F 18 fluorodeoxyglucose (FDG); positron emission tomography (PET); prostate cancer; response

Indexed keywords

ACETATE CARBON 11; BICALUTAMIDE; CUSTIRSEN; DOCETAXEL; FLUORODEOXYGLUCOSE F 18; GOSERELIN; MEDRONATE TECHNETIUM TC 99M; PREDNISONE; RADIOISOTOPE; UNCLASSIFIED DRUG;

ADULT; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER DIAGNOSIS; CANCER GROWTH; CASTRATION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; DRUG UPTAKE; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; TREATMENT RESPONSE;

ACETATES; BONE NEOPLASMS; CARBON; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; TAXOIDS; TREATMENT OUTCOME;

EID: 79951563645     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e318208f140     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96. (Pubitemid 351521864)
2. Hussain M, Tangen CM, Higano C, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol. 2006;24:3984-3990. (Pubitemid 46630748)
3. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-1520. (Pubitemid 39315318)
4. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512. (Pubitemid 39315317)
5. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148-1159.
6. Evelhoch J, Garwood M, Vigneron D, et al. Expanding the use of magnetic resonance in the assessment of tumor response to therapy: workshop report. Cancer Res. 2005;65:7041-7044. (Pubitemid 41161229)
7. Kurhanewicz J, Swanson MG, Nelson SJ, et al. Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J Magn Reson Imaging. 2002;16:451-463. (Pubitemid 35167879)
8. Oyama N, Akino H, Suzuki Y, et al. FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. Nucl Med Commun. 2001;22:963-969. (Pubitemid 32783446)
9. Morris MJ, Akhurst T, Osman I, et al. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology. 2002;59:913-918. (Pubitemid 34522186)
10. Morris MJ, Akhurst T, Larson SM, et al. Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res. 2005;11:3210-3216. (Pubitemid 40627867)
11. Specht JM, Tam SL, Kurland BF, et al. Serial 2-F18-fluoro-2-deoxy- Dglucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP).
12. Schoder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med. 2004;34:274-292. (Pubitemid 39365998)
13. Oyama N, Miller TR, Dehdashti F, et al. C11-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med. 2003;44: 549-555. (Pubitemid 39663421)
14. Oyama N, Akino H, Kanamaru H, et al. C11-acetate PET imaging of prostate cancer. J Nucl Med. 2002;43:181-186. (Pubitemid 34151040)
15. Fricke E, Machtens S, Hofmann M, et al. Positron emission tomography with C11-acetate and F18-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2003;30:607-611. (Pubitemid 36559841)
16. Kotzerke J, Volkmer BG, Neumaier B, et al. Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2002;29:1380-1384. (Pubitemid 44392221)
17. Wachter S, Tomek S, Kurtaran A, et al. C11-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer. J Clin Oncol. 2006;24:2513-2519. (Pubitemid 46630628)
18. Pike VW, Eakins MN, Allan RM, et al. Preparation of C11-acetate-an agent for the study of myocardial metabolism by positron emission tomography. Int J Appl Radiat Isot. 1982;33:505-512.
19. Hamacher K, Coenen HH, Stocklin G. Efficient stereospecific synthesis of no-carrier-added 2-F18-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1986;27:235-238. (Pubitemid 17024868)
20. Lewellen TK, Kohlmyer SG, Miyaoka RS, et al. Investigation of the performance of the general electric ADVANCE positron emission tomograph in 3D mode. IEEE Trans Nucl Sci. 1996;43:2199-2206. (Pubitemid 126771597)
21. Muzi M, Swanson K, Spence A, et al. Initial assessment of an acetate model for membrane biosynthesis in glioma patients. J Nucl Med. 2003;44:216P.
22. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17:3461-3467. (Pubitemid 29517916)
23. Jacene HA, Ishimori T, Engles JM, et al. Effects of pegfilgrastim on normal biodistribution of F18-FDG: preclinical and clinical studies. J Nucl Med. 2006;47:950-956. (Pubitemid 46939947)
24. Yoshimoto M, Waki A, Yonekura Y, et al. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol. 2001;28:117-122. (Pubitemid 32276075)
25. Swinnen JV, Van Veldhoven PP, Timmermans L, et al. Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains. Biochem Biophys Res Commun. 2003;302:898-903. (Pubitemid 36294061)
26. Swinnen JV, Roskams T, Joniau S, et al. Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer. 2002;98:19-22. (Pubitemid 34113412)
27. Rossi S, Graner E, Febbo P, et al. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res. 2003;1: 707-715. (Pubitemid 37025589)
28. Swinnen JV, Vanderhoydonc F, Elgamal AA, et al. Selective activation of the fatty acid synthesis pathway in human prostate cancer. Int J Cancer. 2000; 88:176-179.
29. Pizer ES, Pflug BR, Bova GS, et al. Increased fatty acid synthase as a therapeutic target in androgen-independent prostate cancer progression. Prostate. 2001;47:102-110. (Pubitemid 32336579)
30. Roudier MP, True LD, Higano CS, et al. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol. 2003;34:646-653. (Pubitemid 36875509)
31. Kotzerke J, Volkmer BG, Glatting G, et al. Intraindividual comparison of C11-acetate and C11-choline PET for detection of metastases of prostate cancer. Nuklearmedizin. 2003;42:25-30. (Pubitemid 36231688)
32. Luboldt W, Kufer R, Blumstein N, et al. Prostate carcinoma: diffusionweighted imaging as potential alternative to conventional MR and C11-choline PET/CT for detection of bone metastases. Radiology. 2008;249: 1017-1025.
33. Tuncel M, Souvatzoglou M, Herrmann K, et al. C11-Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer. Nucl Med Biol. 2008;35:689-695.
34. Beheshti M, Vali R, Waldenberger P, et al. Detection of bone metastases in patients with prostate cancer by F18-fluorocholine and F18-fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging. 2008;35: 1766-1774.